Search results: Found 4

Listing 1 - 4 of 4
Sort by
Update on the Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC) in New Era of Personalised Medicine

Authors: ---
Book Series: Frontiers Research Topics ISSN: 16648714 ISBN: 9782889453979 Year: Pages: 95 DOI: 10.3389/978-2-88945-397-9 Language: English
Publisher: Frontiers Media SA
Subject: Medicine (General) --- Oncology
Added to DOAB on : 2018-11-16 17:17:57
License:

Loading...
Export citation

Choose an application

Abstract

Lung Cancer remains a major cause of death in of both women and men in our society. Lung cancer treatment paradigms have changed enormously as we’ve started to understand the genetic complexity and the multiple driver mutations influencing the disease. Therapeutics directed towards, or to inhibit signaling pathways has resulted in increased life spans for our patients. Over the last two decades, we have gone from simple chemotherapy used to treat all, to a personalized medicine approach for the majority. For non-small cell lung cancer patients without driver mutations, the world of immune oncology has arrived. These improved long-term outcomes mean that now our lung cancer patients can live with their cancers, but without progression. The aim of this book is to catalogue the current state of knowledge for the many facets of advanced lung cancer. It describes current treatment approaches for driver mutations, rare mutations, and rare thoracic malignancies such as neuroendocrine tumors. Most importantly, this book addresses the topics of palliative treatment and care which allow our patients to enjoy longer survival with the highest quality of life. We hope you enjoy this e-book. The future is brighter for lung cancer patients and as lung cancer specialists; we finally feel sense optimism about treatment options for our patients.

Towards New Promising Discoveries for Lung Cancer Patients: A Selection of Papers from the First Joint Meeting on Lung Cancer of the FHU OncoAge (Nice, France) and the MD Anderson Cancer Center (Houston, TX, USA)

Authors: --- ---
ISBN: 9783039214518 9783039214525 Year: Pages: 230 DOI: 10.3390/books978-3-03921-452-5 Language: English
Publisher: MDPI - Multidisciplinary Digital Publishing Institute
Subject: Medicine (General) --- Oncology
Added to DOAB on : 2019-12-09 11:49:15
License:

Loading...
Export citation

Choose an application

Abstract

This Special Issue of Cancers (Basel) is mainly dedicated to selecting papers from the talks given during the first Joint Meeting on Lung Cancer (JMLC) between the MD Anderson Cancer Center (Houston, Texas USA) and the Hospital University Federation (HUF) OncoAge (University Côte d’Azur, Nice, France) (Nice, September 2018). The central theme of JMLC is to discuss new advances and exchange ideas regarding lung cancer. Notably, the talks covered different topics on new therapeutic strategies (targeted therapy and immuno-oncology), molecular and cellular biology, biomarkers, and the epidemiology of lung cancer. Special attention was also given to lung cancer in elderly patients. The articles published in this Special Issue covered subjects such as the assessment of new biomarkers and new approaches for the early detection of lung cancer, epidemiological data, and emphasized a place for the newly characterized cellular pathways in lung cancer, which opens room for therapeutic perspectives for lung cancer patients.

Links between Fibrogenesis and Cancer: Mechanistic and Therapeutic Challenges: Mechanistic and Therapeutic Challenges

Author:
ISBN: 9783039217069 9783039217076 Year: Pages: 348 DOI: 10.3390/books978-3-03921-707-6 Language: English
Publisher: MDPI - Multidisciplinary Digital Publishing Institute
Subject: Medicine (General) --- Internal medicine
Added to DOAB on : 2019-12-09 11:49:16
License:

Loading...
Export citation

Choose an application

Abstract

Tissue fibrosis may occur for unknown causes or be the consequence of many pathological conditions including chronic inflammatory or infectious diseases, autoimmune disorders, graft rejection, or malignancy. On the other hand, malignant tumors have been identified in fibrotic tissues decades ago, and now accumulating evidence suggests that fibrotic lesions enhance the risk of cancer in several organs such as liver, lungs, and breast. Disruption of an organ parenchymal cells and of its normal structural scaffold during tissue fibrogenesis appears to induce loss of cell polarity, promoting uncontrolled cell proliferation that may eventually lead to cancer development. Many cellular and molecular abnormalities including aberrant expression of microRNAs, genetic and epigenetic alterations, evasion or delayed apoptosis, unregulated intracellular signal pathways, and dysregulation or defective intercellular communications have been proposed to explain this link between fibrogenesis and carcinogenesis. However, the precise mechanisms of this fibrosis-to-cancer transition remain unclear. This book presents a collection of reviews and original articles summarizing recent advances in understanding the molecular mechanisms of cancer development in fibrotic organs.

Keywords

lung cancer --- renal injury --- fibrosis --- crizotinib --- anaplastic lymphoma kinase --- cystic formation --- pulmonary fibrosis --- butylidenephthalide --- SOX2 --- type I collagen --- bleomycin --- YAP --- TAZ --- Hippo pathway --- fibrosis --- cancer --- mechanotransduction --- TGF-? --- Wnt --- uterine fibroid --- leiomyoma --- tumor --- tumor necrosis factor ? --- cytokine --- growth factor --- inflammation --- clinical symptoms --- pathophysiology --- therapy --- hepatocellular carcinoma --- cirrhosis --- regeneration --- inflammation --- cytokines --- genetic instability --- reactive oxygen species --- idiopathic pulmonary fibrosis (IPF) --- lung cancer (LC) --- non-small cell lung cancer (NSCLC) --- acute lung injury --- protein S --- apoptosis --- signal pathway --- Erk1/2 --- lipopolysaccharide --- uterine fibroid --- leiomyoma --- smooth muscle tumor of uncertain malignant potential --- leiomyosarcoma --- myometrium --- immunohistochemistry --- marker --- pathology --- tumor --- diagnosis --- cancer-associated fibroblasts --- tumor microenvironment --- nanoparticles --- breast cancer --- antitumor efficacy --- cirrhosis --- HBV --- HCV --- hepatocellular carcinoma --- idiopathic pulmonary fibrosis --- lung cancer --- pathogenesis --- common pathways --- hepatocellular carcinoma (HCC) --- fibrosis --- cancer-associated fibroblasts (CAFs) --- hepatic stellate cells (HSCs) --- tumor microenvironment --- hepatocellular carcinoma --- non-alcoholic steatohepatitis --- fibrosis --- hepatic stellate cells --- extracellular matrix --- carcinogenesis --- angiogenesis --- cancer-associated fibroblasts --- extracellular matrix --- fibrosis --- heterogeneity --- interstitial fluid pressure --- metabolic reprogramming --- transforming growth factor-? --- tumor stiffness --- GPR40 --- GPR120 --- DHA --- omega-3 fatty acid --- SREBP-1 --- hepatocytes --- EMT --- lncRNA --- metastasis --- miRNA --- SMAD --- TGF-? --- targeted therapy --- tumor microenvironment --- n/a

Circulating Tumor Cells: Finding Rare Events for A Huge Knowledge of Cancer Dissemination

Author:
ISBN: 9783039286980 / 9783039286997 Year: Pages: 366 DOI: 10.3390/books978-3-03928-699-7 Language: eng
Publisher: MDPI - Multidisciplinary Digital Publishing Institute
Subject: Medicine (General)
Added to DOAB on : 2020-06-09 16:38:57
License:

Loading...
Export citation

Choose an application

Abstract

The analysis of circulating tumor cells (CTCs) as a real-time liquid biopsy approach can be used to obtain new insights into metastasis biology, and as companion diagnostics to improve the stratification of therapies and to obtain insights into the therapy-induced selection of cancer cells. In this book, we will cover all the different facets of CTCs to assemble a huge corpus of knowledge on cancer dissemination: technologies for their enrichment, detection, and characterization; their analysis at the single-cell level; their journey as CTC microemboli; their clinical relevance; their biology with the epithelial-to-mesenchymal transition (EMT); their stem-cell properties; their potential to initiate metastasis at distant sites; their ex vivo expansion; and their escape from the immune system.

Keywords

circulating tumor cells --- circulating tumor DNA --- liquid biopsy --- metastatic colorectal cancer --- FOLFIRINOX --- circulating tumor cells --- CTC --- liquid biopsy --- CTM --- CTMat --- CTC biology --- CTC capture technology --- metastasis --- circulating tumor cells (CTCs) --- hepatocellular carcinoma (HCC) --- castration resistant prostate cancer (CRPC) --- epithelial-to-mesenchymal transition (EMT) --- fibronectin --- integrin B1 --- SLUG --- major histocompatibility complex class I (MHCI) --- immunomodulation --- bone marrow --- melanoma --- disseminated tumor cells --- solid cancers --- single-cell analysis --- enrichment and detection technologies --- flow cytometry --- tumor stem cells --- HMB-45 --- CD133 --- locally advanced rectal cancer --- circulating tumor cells --- RAD23B --- thymidylate synthase --- chemoradioresistance --- liquid biopsy --- circulating tumor cells --- epithelial–mesenchymal transition --- stem cells --- early breast cancer --- prostate cancer (PCa) --- circulating tumor cells (CTC) --- liquid biopsy --- circulating tumor cells --- metastasis --- xenograft models --- breast cancer --- prostate cancer --- CTC --- AR --- AR-V7 --- ctRNA --- exosome --- circulating tumor cells --- hematological cells --- neutrophils --- platelets --- liquid biopsy --- circulating tumor cells --- melanoma --- liquid biopsy --- EPISPOT --- CellSearch® --- liquid biopsy --- CTCs --- immune checkpoint inhibitors --- PD-L1 expression --- NSCLC --- small-cell lung carcinoma --- circulating tumor cells --- microfluidics --- gene expression analysis --- synaptophysin --- chromogranin A --- rovalpituzumab tesirine --- leukocyte-derived extracellular vesicles --- immunofluorescence imaging --- EpCAM enrichment --- CellSearch --- EasyCount slides --- ACCEPT --- CTC --- heterogeneity --- liquid biopsy --- liquid surgery --- clinical utility --- circulating tumor cells (CTCs) --- glioma --- biomarker --- rVAR2 --- malaria --- enrichment and detection technologies --- prostate cancer --- biomarkers --- circulating tumor cells --- androgen receptor --- ARV7 --- abiraterone --- enzalutamide --- metastasis --- tumor-initiating cells (TICs) --- circulating tumor cells (CTCs) --- CTC-derived xenografts --- CTC-derived ex vivo models --- cerebrospinal liquid biopsy --- in vivo flow cytometry --- tumor biomarkers --- circulating tumor cells --- ctDNA --- miRNA --- exosomes --- emboli --- targeted therapy --- circulating tumor cells --- tumor cell dissemination --- immune system --- microbiome --- circulating tumor cells (CTCs) --- clinical trials --- breast cancer --- CTC-based treatment decisions --- circulating tumour cells --- colorectal cancer --- colorectal surgery --- microsatellite instability --- microfluidics --- immunophenotyping --- fish --- liquid biopsy --- circulating leukemia cells --- circulating plasma cells --- n/a

Listing 1 - 4 of 4
Sort by
Narrow your search